Status:
RECRUITING
Use of an Ultra-rapid BRCA1/2 Status Screening Test in Diagnostic and Theranostic Indication: Performance and Interest for Patients and Practitioners
Lead Sponsor:
Centre Georges Francois Leclerc
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The time taken to obtain the results of germline mutations in BRCA1 and BRCA2 has become a major issue in adapting the therapeutic management of patients, particularly those with breast cancer. The t...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Indication for oncogenetic consultation with a wide panel test including BRCA1/2 (gold standard) as part of the standard theranostic and diagnostic management of breast cancer.
- The patient agrees to take part in the study, to follow all the study procedures and to complete the questionnaires sent during the consultation or by email.
- Diagnosis of the disease ≤ 6 months
- The patient must be affiliated to the social security system.
Exclusion
- Concomitant disorder or condition likely to compromise understanding of study information or completion of questionnaires
- Patients who do not have an email address and/or do not have internet access or tools to connect to the internet
- Women who are pregnant, may become pregnant or are breast-feeding
- Persons deprived of their liberty or under guardianship (including curatorship)
- Inability to undergo trial monitoring for geographical, social or psychological reasons.
Key Trial Info
Start Date :
June 12 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 12 2026
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06111417
Start Date
June 12 2024
End Date
September 12 2026
Last Update
April 22 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Georges-François Leclerc
Dijon, France, 21000
2
Institut Rafaël
Levallois-Perret, France, 92300